DOCSLIB.ORG

Us 2019 / 0202839 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Us 2019 / 0202839 A1 US 20190202839A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0202839 A1 JAIN et al. ( 43 ) Pub . Date: Jul. 4 , 2019 (54 ) NOVEL CYTOTOXIC AGENTS AND Publication Classification CONJUGATES THEREOF (51 ) Int . CI. (71 ) Applicant : POLYTHERICS LIMITED , C07D 498 / 18 (2006 .01 ) Cambridge (GB ) A61K 31 /537 ( 2006 . 01) A61K 47/ 68 (2006 . 01 ) ( 72 ) Inventors: Nareshkumar JAIN , Ringoes, NJ A61P 35 /00 ( 2006 .01 ) (US ) ; Sanjeevani GHONE , Plainsboro , 2 ) U .S . CI. NJ (US ) ; Sean SMITH , Hamilton , NJ PO . C07D 498 / 18 (2013 . 01 ) ; A61K 31/ 537 (US ) ; Ian GLASSFORD , King of ( 2013 .01 ) ; A61P 35 / 00 ( 2018 .01 ) ; A61K Prussia , PA (US ) ; Sylvia J . 47 /6803 ( 2017 .08 ) ; A61K 47/ 6851 (2017 .08 ) DEGRADO , Newtown , PA (US ) ; Fu -an KANG , Collegeville , PA (US ) ; Senzhi ZHAO , Bensalem , PA (US ) (57 ) ABSTRACT (21 ) Appl. No. : 16 /332 , 797 Provided herein are novel maytansinoid compounds of gen (22 ) PCT Filed : Sep . 15 , 2017 eral formula I . Also provided herein are conjugates com prising the compounds linked to a binding protein via a ( 86 ) PCT No. : PCT/GB2017 / 052731 linker , and conjugating reagents comprising the compounds attached via a linker to at least one functional group capable $ 371 (c ) ( 1 ) , of reacting with a binding protein . Also provided herein are ( 2 ) Date : Mar. 13 , 2019 pharmaceutical compositions comprising the compounds ( 30 ) Foreign Application Priority Data and conjugates, therapeutic methods and uses involving the compounds and conjugates , for example in cancer therapy, Sep . 15 , 2016 (GB ) . .. .. 1615725. 7 and novel synthetic processes . Patent Application Publication Jul . 4 , 2019 Sheet 1 of 3 US 2019 /0202839 A1 Maytansinoid derivatives SK -BR - 3 cell line • 3 v DM1 Cellviability(%) III . Compound Concentration (nM ) Figure 1 Maytansinoid Derivatives Karpas - 299 cell line # 3 Cellviability(%) V DM1 0.0001 100 Concentration ( nM ) Figure 2 -Patent Application- Publication - .Jul. 4 , 2019 . Sheet. 2 of . 3 .US. 2019 / 0202839 A1. W Vehicle W 29 ( 30 mg/ kg ) Kadcyla® ( 30 mg/ kg ) IIIIIITITITITI IIIIII TI IIIIITITUTT D IIIIIIIIIIIIIIIIIII IIIIII DIIII IIIIII LLLLLLL IIIIIIIII DIT IIIIIIIIIII Meantumourvolume(r III LIIT LLLLLLL LLLLLLLL IIIIIIIII IIIIII JULI IIIIIIIIIII LLLLLLLLL IIIIII LLLLLLLL III LIITLI IIIIIII III HILLIP IT LIIIII IIIIII ITIT IIIIII TTTTTT TITITITI LLLLLILL IIIIII LIITUN IIIII TILL LLLLLL UUUUUUITIL • 14 14 © 14 Days post treatment Figure 3 Patent Application Publication Jul. 4 , 2019 Sheet 3 of 3 US 2019 / 0202839 A1 Degradation product A Degradation Product B 0 78 %totaldrugrelatedionsobserved ° 6 4 7 6 4 I Days incubation in serum Figure 4A Degradation Product C - Degradation Product D VIZ W 26 %totaldrugrelatedionsobserved ó À í ó À í ? Days incubation in serum Figure 4B US 2019 /0202839 A1 Jul . 4 , 2019 NOVEL CYTOTOXIC AGENTS AND -continued CONJUGATES THEREOF OH FIELD OF INVENTION OMe [0001 ] This invention relates to novel cytotoxic agents , novel conjugates , particularly antibody - drug conjugates , and intermediates for making the conjugates , including novel conjugating reagents . It also relates to a novel process for making cytotoxic agents . BACKGROUND TO THE INVENTION [0002 ] Much research has been devoted in recent years to ?? ? . the conjugation of therapeutic agents as payloads to peptides and proteins for a wide range of applications. The protein or Maytansinol peptide itself may have therapeutic properties , and / or it may be a binding protein . In addition , conjugation to polymers [0005 ] U . S . Pat. No . 4 , 190 ,580 described a method of has been used to improve the properties of certain therapeu synthesis of maytansinoids , while U . S . Pat . No . 4 , 260 , 608 tic agents . For example , water soluble , synthetic polymers , identified a number of maytansine derivative compounds particularly polyalkylene glycols, are widely used to conju with potent anti- microbial and anti tumour activities as a gate therapeutically active peptides or proteins . These thera result of their anti -mitotic effects upon cells . U . S . Pat. No. peutic conjugates have been shown to alter pharmacokinet 4 , 260 ,608 disclosed maytansine derivatives with an option ics favourably by prolonging circulation time and decreasing ally substituted alkyl group at the R3 position . Since then clearance rates , decreasing systemic toxicity , and in several numerous structure - activity relationship studies have been cases , displaying increased clinical efficacy . The process of performed to determine other potent structures of maytansi covalently conjugating polyethylene glycol, PEG , to pro noids. Kawai et al . , Chem . Pharm . Bull. 32 ( 9 ) , 3441 -3451 teins and other payloads is commonly known as “ PEGY ( 1984 ) published a number of structures that were modified lation ” . at the C3 position of Maytansinol, which displayed potent [ 0003] Binding proteins ( i. e . proteins or peptides capable anti - tumour effects in vivo . EP O 004 466 , U . S . Pat. No . of binding to a binding partner on a target ) , particularly 4 , 137 ,230 and WO 2012 / 061590 all describe novel may antibodies or antibody fragments , are frequently used in tansinoids. Various modifications of maytansinoids are conjugates . For example , they may be conjugated to cyto described in US 2009 / 258870 , Taft et al , Chem . Eur. J . 2012 , toxic agents and chemotherapy drugs to produce antibody 18 , 880 - 886 , and Harmrolfs et al , Beilstein J . Org . Chem . drug conjugates (ADCs ) , allowing targeted delivery of such 2014 , 10 , 535 - 543 . agents to specific tissues or structures , for example particular 10006 ]. Well -known maytansinoids include those known as cell types or growth factors , minimising the impact on DM1 and DM4 as described within U . S . Pat . No . 5 ,208 , 020 normal, healthy tissue and significantly reducing the side and WO2004 /103272 . These have the structures : effects associated with chemotherapy treatments . Such con jugates have extensive potential therapeutic applications in several disease areas , particularly in cancer . HS . 00041 Kupchan et al. , J . Am . Chem . Soc . , 94 , 1354 ( 1972 ) first isolated Maytansine from the bark of the African shrub Maytenus ovatus, where it was noted for its anti- leukemic JOMe properties . Maytansinoids, such as maytansinol and C - 3 esters of maytansinol were found to be made by microbes ( U . S . Pat. No. 4 , 151 ,042 ) , mosses (Sakai et al , J . Nat . Prod ., 51 ( 5 ) , 845 - 850 , 1988 ) , and could also be generated by synthetic routes (Kupchan et al . , J . Med . Chem ., 21, 31 - 37 , VU 1978 , Higashide et al. , Nature 270 , 721 - 722 , 1977 ) . May tansine and maytansinol have the structures : DM1 orMertansine DM4 uillllll HS 111 OMe OMe N LO O H HO O Maytansine US 2019 /0202839 A1 Jul . 4 , 2019 [0007 ] Ansamitocins are a sub -group of maytansinoids, payloads need to be conjugated efficiently with an antibody the synthesis of which is described by Taft et al, ChemBio using a conjugation technology which allows more stable Chem 2008 , 9 , 1057 - 1060 . A well - known ansamitocin is ADCs to be generated . There is also a need for ADCs which AP - 3 , which has the structure : show greater efficacy or potency in relevant cell or animal models of cancers , or alternatively , show a similar level of efficacy /potency but a reduced amount of non - specific tox icity within the cell or test subject . [0011 ] We have now found that certain novel maytansi noid compounds possess improved cytotoxic activity , and are particularly suited for inclusion in conjugates with binding proteins . The maytansinoids further have improved stability compared with comparator compounds. We have also found a novel method of synthesis which enables efficient preparation of these novel compounds as well as a novel and improved method of synthesis of other maytansi .) noids . OHON SUMMARY OF THE INVENTION [ 0012 ] The invention provides a compound of the general formula ( I ) or a salt thereof: [0008 ] Maytansinoids and maytansinoid esters were sub sequently used as a cytotoxic payload within an ADC context within EP 0 425 235 and have been used extensively since, see for example Liu et al , Proc . Natl. Acad . Sci. USA , 93 , 8618 - 8623 ( 1996 ) ; and Kieda et al, Clin . Cancer Res . , 15 ( 12 ) , 2009 . Widdison et al, J . Med . Chem . 49 , 4392 - 4408 (Rein (2006 ) described the thiol- linked DM1 and DM4 maytansi 0 0 ' Rg noid payloads. These payloads were conjugated via a two step process in which first a heterobifunctional, thiol- con taining linker was reacted with lysine residues within the Rd antibody , followed by conjugation of the thiol- containing payloads to the linker by disulfide exchange . An alternative means of producing ADCsby this two - step process is by use of a succinimidyl trans - 4 - maleimidylmethyl) cyclohexane RA - 1 - carboxylate ( SMCC ) heterobifunctional linker , which has a succinimide group at one end to react with lysine residues within the antibody and a maleimide group at the other end Rb Rovó to react with the thiol group of the maytansinoid . The commercially -available pharmaceutical Kadcyla® is an in which R represents a group — Y - OH , — Y — 0 ~ R * , example of an ADC produced using an SMCC linker with a - Y - SH , - Y - S R * , - Y - S ( O ) NH - R " , - Y - NHS DM1 maytansinoid payload . Kadcyla® is currently one of ( 0 ) 2 - R * , - Y - C ( O ) H , — Y - CO , H , - Y - C ( O ) - R * , the leading ADCs in the clinic and is used for
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer
    cancers Article IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer Mai Badarni 1,2, Manu Prasad 1,2 , Artemiy Golden 3, Baisali Bhattacharya 1,2, Liron Levin 4,5, Ksenia M. Yegodayev 1,2, Orr Dimitstein 2,6, Ben-Zion Joshua 2,7, Limor Cohen 1,2, Ekaterina Khrameeva 3, Dexin Kong 8 , Angel Porgador 1,2, Alex Braiman 1,2, Jennifer R. Grandis 9, Barak Rotblat 5,10,* and Moshe Elkabets 1,2,* 1 The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; [email protected] (M.B.); [email protected] (M.P.); [email protected] (B.B.); [email protected] (K.M.Y.); [email protected] (L.C.); [email protected] (A.P.); [email protected] (A.B.) 2 Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; [email protected] (O.D.); [email protected] (B.-Z.J.) 3 Center of Life Sciences, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia; [email protected] (A.G.); [email protected] (E.K.) 4 Bioinformatics Core Facility, National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; [email protected] 5 The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel 6 Department of Otolaryngology—Head and Neck Surgery, Soroka University Medical Center, Beer-Sheva 84105, Israel 7 Citation: Badarni, M.; Prasad, M.; Department of Otorhinolaryngology and Head & Neck Surgery, Barzilay Medical Center, Ashkelon 7830604, Israel Golden, A.; Bhattacharya, B.; Levin, 8 School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, China; [email protected] L.; Yegodayev, K.M.; Dimitstein, O.; 9 Department of Otolaryngology—Head and Neck Surgery, University of California San Francisco, Joshua, B.-Z.; Cohen, L.; Khrameeva, San Francisco, CA 94143, USA; [email protected] E.; et al.
    [Show full text]
  • Activating Death Receptor DR5 As a Therapeutic Strategy for Rhabdomyosarcoma
    International Scholarly Research Network ISRN Oncology Volume 2012, Article ID 395952, 10 pages doi:10.5402/2012/395952 Review Article Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma Zhigang Kang,1, 2 Shi-Yong Sun,3 and Liang Cao1 1 Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA 2 Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., NCI Frederick, Frederick, MD 21702, USA 3 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA Correspondence should be addressed to Liang Cao, [email protected] Received 4 January 2012; Accepted 24 January 2012 Academic Editors: E. Boven and S. Mandruzzato Copyright © 2012 Zhigang Kang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. It is believed to arise from skeletal muscle progenitors, preserving the expression of genes critical for embryonic myogenic development such as MYOD1 and myogenin. RMS is classified as embryonal, which is more common in younger children, or alveolar, which is more prevalent in elder children and adults. Despite aggressive management including surgery, radiation, and chemotherapy, the outcome for children with metastatic RMS is dismal, and the prognosis has remained unchanged for decades. Apoptosis is a highly regulated process critical for embryonic development and tissue and organ homeostasis. Like other types of cancers, RMS develops by evading intrinsic apoptosis via mutations in the p53 tumor suppressor gene.
    [Show full text]
  • Estado Clínico-Oncológico De Pacientes Incluidos En El Ensayo Clínico RANIDO Tratados Con Racotumomab O Nimotuzumab
    ISSN-E: 1990-7990 RNPS:2008 Univ Méd Pinareña. Septiembre-Diciembre 2020; 16(3):e503 ARTÍCULO ORIGINAL Estado clínico-oncológico de pacientes incluidos en el ensayo clínico RANIDO tratados con Racotumomab o Nimotuzumab Clinical-oncological status of patients included in RANIDO clinical trial treated with Racotumomab or Nimotuzumab César Adrián Blanco-Gómez1 , Ana Lázara Delgado-Reyes1 , Laura Elena Valdés-Rocubert1 , Rolando David Hernández-Godínez2 , Martha Elena Gómez-Vázquez3 1Universidad de Ciencias Médicas de Pinar del Río. Facultad de Ciencias Médicas “Dr. Ernesto Guevara de la Serna”. Pinar del Río, Cuba. 2Universidad de Ciencias Médicas de Granma. Hospital Provincial Universitario “Carlos Manuel de Céspedes”. Granma, Cuba. 3Universidad de Ciencias Médicas de Pinar del Río. Policlínico Universitario “Raúl Sánchez Rodríguez”. Pinar del Río, Cuba. Recibido: 16 de febrero de 2020 | Aceptado: 25 de abril de 2020 | Publicado: 17 de mayo de 2020 Citar como: Blanco-Gómez CA, Delgado-Reyes AL, Valdés-Rocubert LE, Hernández-Godínez RD, Gómez-Vázquez ME. Estado clínico- oncológico de pacientes incluidos en el ensayo clínico RANIDO tratados con Racotumomab o Nimotuzumab. Univ Méd Pinareña [Internet]. 2020 [citado: Fecha de Acceso]; 16(3):e503. Disponible en: http://www.revgaleno.sld.cu/index.php/ump/article/view/503 RESUMEN Introducción: RANIDO es un ensayo clínico extendido hasta la atención primaria de salud con el objetivo de evaluar la eficacia de los productos biotecnológicos cubanos Racotumomab y Nimotuzumab para el tratamiento del cáncer de pulmón de células no pequeñas. Objetivo: caracterizar clínico-oncológicamente a los pacientes incluidos en el ensayo clínico RANIDO tratados con Racotumomab y Nimotuzumab en Pinar del Río entre enero de 2013 y enero de 2018.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • International Nonproprietary Names for Pharmaceutical Substances (INN)
    WHO Drug Information, Vol. 26, No. 3, 2012 Recommended INN: List 68 International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 68 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in Cumulative List No. 14, 2011 (available in CD-ROM only). Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 68 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la Liste récapitulative No.
    [Show full text]
  • Therapeutic Targeting of the IGF Axis
    cells Review Therapeutic Targeting of the IGF Axis Eliot Osher and Valentine M. Macaulay * Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK * Correspondence: [email protected]; Tel.: +44-1865617337 Received: 8 July 2019; Accepted: 9 August 2019; Published: 14 August 2019 Abstract: The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging. Keywords: IGF; type 1 IGF receptor; IGF-1R; cancer; acromegaly; ophthalmopathy; IGF inhibitor 1. Introduction Insulin like growth factors (IGFs) are small (~7.5 kDa) ligands that play a critical role in many biological processes including proliferation and protection from apoptosis and normal somatic growth and development [1]. IGFs are members of a ligand family that includes insulin, a dipeptide comprised of A and B chains linked via two disulfide bonds, with a third disulfide linkage within the A chain.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al
    US009 161992B2 (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies et al. (45) Date of Patent: Oct. 20, 2015 (54) P97 FRAGMENTS WITH TRANSFER 4,683.202 A 7, 1987 Mullis ACTIVITY 4,704,362 A 11/1987 Itakura et al. 4,766,075 A 8, 1988 Goeddeletal. (71) Applicant: biosis Technologies, Inc., Richmond 4,800,1594,784.950 A 11/19881/1989 MullisHagen et al. (CA) 4,801,542 A 1/1989 Murray et al. 4.866,042 A 9, 1989 Neuwelt (72) Inventors: Wilfred Jefferies, South Surrey (CA); 4,935,349 A 6/1990 McKnight et al. Mei Mei Tian, Coquitlam (CA): 4.946,778 A 8, 1990 Ladner et al. Timothy Vitalis, Vancouver (CA) 5,091,513 A 2f1992 Huston et al. 5,132,405 A 7, 1992 Huston et al. (73) Assignee: biOasis Technologies, Inc., British 5, 186,941 A 2f1993 Callahan et al. Columbia (CA) 5,672,683 A 9, 1997 Friden et al. 5,677,171 A 10, 1997 Hudziak et al. c - r 5,720,937 A 2f1998 Hudziak et al. (*) Notice: Subject to any disclaimer, the term of this 5,720,954. A 2f1998 Hudziak et al. patent is extended or adjusted under 35 5,725,856 A 3, 1998 Hudziak et al. U.S.C. 154(b) by 0 days. 5,770,195 A 6/1998 Hudziak et al. 5,772,997 A 6/1998 Hudziak et al. (21) Appl. No.: 14/226,506 5,844,093 A 12/1998 Kettleborough et al. 5,962,012 A 10, 1999 Lin et al.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]